Ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis

Interesting result for MS patients management…

Ocrelizumab showed a higher efficacy regarding relapses and disability progression in RRMS patients compared to beta-1a subcutaneous interferon in two pivotal phase III trials. Results are still expected for ORATORIO study which tested the treatment in PPMS… via Genentech: Press Releases


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s